Phase I study of pexidartinib (PLX3397) in children with refractory leukemias and solid tumors including neurofibromatosis type I (NF1) related plexiform neurofibromas (PN).

Lauren Hittson,John Glod,Melissa Amaya,Joanne Derdak,Brigitte C. Widemann,Rosandra N. Kaplan

Phase I study of pexidartinib (PLX3397) in children with refractory leukemias and solid tumors including neurofibromatosis type I (NF1) related plexiform neurofibromas (PN).

2017

Lauren Hittson
John Glod
Melissa Amaya
Joanne Derdak
Brigitte C. Widemann
Rosandra N. Kaplan

10546Background: Refractory tumors remain a significant treatment challenge, and novel approaches targeting the tumor microenvironment may hold promise. Pexidartinib, an oral inhibitor of tyrosine ...

Keywords:

Refractory
Pexidartinib
Pathology
Neurofibromatosis type I
Plexiform neurofibroma
Medicine
Tyrosine
phase i study
Tumor microenvironment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations